相关实验视频

Updated: Jun 26, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

双重FDG/PSMA PET成像用于预测PSMA-RLT期间mCRPC的基于病变的进展

Florian Rosar¹, Caroline Burgard¹, Scott David¹

¹Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Scientific reports

|May 17, 2024

概括

使用PSMA-配体吸收率和FDG吸收率的新评分系统可以预测接受放射性配体治疗的转移性前列腺癌患者的治疗反应. 这有助于识别可能进展的病变,指导个性化治疗策略.

科学领域:

核医学就是核医学.
在瘤学瘤学.
放射性药物疗法是一种放射性药物疗法.

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 患者通常在PET扫描上具有不同的[18F]FDG和PSMA配体吸收的病变.
预测这些"不匹配"病变的治疗反应对于有效的放射性连接体疗法 (RLT) 至关重要.

研究的目的:

制定定量标准来识别预测PSMA向RLT反应不良的mCRPC病变.
评估基线PET成像特征对早期病变进展的预测价值.

主要方法:

在使用基线[18F]FDG和[68Ga]Ga-PSMA-11PET扫描对22名患者267例mCRPC转移的回顾性分析.
对[18F]FDG SUVmax/[68Ga]Ga-PSMA-11 SUVmax 分数 (FPQ) 的计算.
在两次177Lu-PSMA-617 RLT循环后评估损伤反应,使用后续[18F]FDG PET和ROC分析来确定预测切线.

主要成果:

进展的病变与不进展的病变相比,显著降低了基线[68Ga]Ga-PSMA-11 SUVmax和更高的FPQ.
[68Ga]Ga-PSMA-11 SUVmax (AUC:0.89) 和FPQ (AUC:0.90) 显示出对进展的预测能力.
综合两个参数的联合临床评分实现了更高的预测性能 (AUC:0.94).

结论:

低基线[68Ga]Ga-PSMA-11 SUVmax和高FPQ预测PSMA向RLT期间早期的病变进展.
开发的临床评分有效预测早期进展,并可以定量识别"不匹配"的病变.
这些标准可能有助于为mCRPC个性化RLT战略.

关键词:

德国联邦航空公司 (FDG)不匹配的不匹配情况在PSMA上,PSMA可以在PSMA上进行交易.放射性合物治疗是一种放射性合物治疗.mCRPC 的使用情况.

更多相关视频

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

相关概念视频

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...